CAPRICOR THERAPEUTICS, INC. (CAPR) Stock
1 member of Congress disclosed 1 trade in CAPR since 2017: 0 purchases and 1 sale, most recently Roger W. Marshall (sale, Jul 27, 2017). 5 of the hedge funds AlphaScala tracks reported CAPR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $19.61M.
Which members of Congress traded CAPRICOR THERAPEUTICS, INC. (CAPR)?
Most recent: Roger W. Marshall (sale, Jul 27, 2017); records start Jul 27, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Roger Marshall R-KS · House | 2017-07-27 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all CAPR political trades →Which hedge funds own CAPR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 814K | $19.61M | +51% |
| Millennium Management Israel Englander | 234K | $5.63M | -34% |
| D.E. Shaw David Shaw | 124K | $2.98M | NEW |
| Marshall Wace | 98K | $2.36M | -10% |
| Point72 Steve Cohen | 95K | $2.28M | -88% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →CAPR price chart
Powered by TradingViewWhat does CAPRICOR THERAPEUTICS, INC. do?
Capricor Therapeutics Inc. is a clinical-stage biotechnology company focused on developing transformative cell and exosome-based therapeutics for rare diseases with high unmet medical needs, particularly Duchenne muscular dystrophy (DMD), which causes muscle degeneration and premature death. Its lead product candidate, deramiocel (formerly CAP-1002), is an allogeneic cardiac-derived cell therapy currently advancing through late-stage clinical development for DMD cardiomyopathy. The company leverages its proprietary StealthX platform for exosome technology, enabling preclinical research into targeted delivery of oligonucleotides, proteins, small molecules, and applications in vaccinology. Additional pipeline candidates include engineered exosomes and exosome-based vaccines aimed at addressing various unmet needs in healthcare. Capricor Therapeutics Inc. operates in the biotechnology sector, emphasizing innovative treatments derived from strong academic partnerships with leading research institutions. Founded in 1996 and headquartered in San Diego, California, the company plays a key role in advancing novel therapies for neuromuscular and related disorders.